

# **Temí Folaranmi MBChB, MPH, MPP**

temitope.x.folaranmi@gsk.com | Cell: +1 2159332972

## **PROFESSIONAL PROFILE**

---

Physician executive and global public health leader with extensive experience in healthcare, medical affairs, vaccines/drug development, and commercialization. Strategic leader with demonstrated success in global medical affairs execution, product launch readiness, policy shaping, evidence generation, and stakeholder engagement across geographies. Adept at leading through influence in matrixed environments, building medical capabilities, and aligning global medical strategies to local market needs. Known for fostering high-performing, cross-functional teams and delivering medically relevant outcomes.

## **RELEVANT EXPERIENCE**

---

### ***Vice President, U.S. Medical and Clinical Affairs, Vaccines***

**GlaxoSmithKline Plc, Philadelphia, PA**

**Mar. 2022- Present**

- Serves as senior vaccines physician and scientific spokesperson for GSK Vaccines.
- Led the strategic medical launch of blockbuster vaccines, including RSV and meningococcal vaccines, and lifecycle management of a vaccine portfolio of 16 assets in the pediatric, adolescent, and older adult categories.
- Lead external stakeholder communications to vaccine opinion leaders and communicates the value of vaccines to both scientific and non-scientific communities in the U.S
- Accountable for the development and execution of globally and commercially aligned medical plans that provide comprehensive evidence-generation and data communication strategies
- Coordinates the generation of medical insights across the US operating units and integrates these to inform global medical affairs priorities where appropriate.
- Oversight for medical-associated content/opinion for regulatory documents pertaining to vaccines
- Ensures appropriate level of medical support to vaccine clinical operations in the U.S.
- Member of U.S. medical affairs leadership team, U.S. vaccines commercial leadership team, and global labeling committee
- Leads strategic recruitment of a high-performing medical team with the right capabilities and performance-driven culture.

### ***Executive Director and Therapeutic Area Lead, Pneumococcal Vaccines***

**Merck and Co, North Wales, PA**

**Dec. 2019 – Mar. 2022**

- Strategic leadership and responsibility for managing global teams responsible for the development, and execution of global scientific & medical affairs strategic plan for pneumococcal vaccines portfolio including global medical launch of Merck's 15-valent pneumococcal conjugate vaccine and lifecycle management of a 23-valent pneumococcal polysaccharide vaccine in key markets
- Led global engagement with international scientific leaders and other key stakeholders (including NITAGs guideline committees, payers, public groups, government officials, medical societies) about Merck's pneumococcal vaccines clinical development program.
- Led development and implementation of a competitive response framework to address inaccurate narrative regarding Merck's vaccines by the competition and strategic oversight for local data generation studies
- Led global medical launch preparedness for pneumococcal vaccine, strategic support for various product development teams, and policy forecasts for pipeline products.
- Drove planning and implementation of global, regional, and key country expert input events such as advisory boards and expert input forums to medical and commercial strategy.

- Member of infectious disease/vaccines medical affairs leadership team. Ensures alignment and awareness of global priorities with cross-functional colleagues from CORE, Policy, Market Access, and Commercial, and other functions as warranted.
- Led consolidation of actionable medical insights from countries and regions to inform company decisions and ensures all scientific exchange for pneumococcal vaccines aligns with a single global scientific communications platform.
- Contributed to the planning, development, and implementation of medical education programs to enhance the public's perception of the value of vaccines and improve vaccine utilization.
- Ensured recruitment and retention of strong talents for the medical affairs organization

***Global Director Medical Affairs, Pneumococcal Vaccines***

**Merck and Co, North Wales, PA**

**Aug. 2017 – Dec. 2019**

***Key Accomplishments***

- Led development of a 5-year medical affairs strategic plan for pneumococcal vaccines including pre-launch strategy for a 15-valent conjugate vaccine.
- Provided medical affairs inputs that informed leadership's discussion on Merck's integrated strategy for pneumococcal vaccines, including licensed PPSV23 and several investigational PCV candidates.
- Successful dissemination of V114 pneumococcal vaccine clinical trials data to various scientific stakeholders including CDC/ACIP Pneumococcal Workgroup, Taiwan CDC, ATAGI among others
- Led development of pneumococcal vaccines SMART plan and co-presented plan to GMA senior leadership.
- Delivered keynote presentations on pneumococcal vaccination in various countries and successfully executed various Merck medical education programs
- Planning and execution of advisory boards on pneumococcal vaccines to inform PDT strategy.
- Led company-wide dissemination of ACIP policy updates on pneumococcal vaccines.
- Contributed to the development of the One-Merck Position on PCV13-PPSV23 sequential policy and presented the position to the Merck Vaccines Integrated Leadership Team and Merck executive board.
- Provided subject matter expertise to inform commercial strategies and scenario planning for PPSV23 and V114 in anticipation of ACIP policy change.

***Medical Epidemiologist (Senior Service Fellow)***

**Centers for Disease Control, Global Immunization Division, Atlanta, GA**

**Sept 2016 to Sept 2017**

- The focal point for routine immunization activities in Nigeria at the CDC Headquarters.
- Provided technical oversight for polio and routine immunization activities in 184 districts supported by the National Stop Transmission of Polio (NSTOP) program.
- Provided technical assistance in the planning and implementation of supplementary immunization activities (SIA) to stop the transmission of wild poliovirus among high-risk populations.
- Led the conceptualization, development and implementation of a \$500,000 incentive-based demand creation project for routine immunization in northern Nigeria.

***Consultant***

**World Health Organization, Western Pacific Regional Office, Manila, Philippines**

**July-Sept 2016**

- Synergized surveillance data received from multiple sources to conduct evidence-based risk assessment of potential outbreaks; supported the development of multisource information for timely risk assessment and decision-making.
- Supported the development of an adjunct Joint Reporting Form on influenza vaccine use.
- Provided technical assistance for the US-CDC annual review and 10th Bi-regional Meeting of National Influenza Centers and Influenza Surveillance in the Western Pacific and South-East Asia Regions.
- Co-developed documents and work plan for a \$5-million CDC-funded multi-year cooperative agreement on influenza surveillance.

***Epidemic Intelligence Service Officer*****Centers for Disease Control, Division of Bacterial Diseases, Atlanta GA****July 2014- June 2016*****Key Accomplishments***

- Lead author and co-author of two ACIP policy recommendations for the use of meningococcal serogroup B vaccines among high-risk groups, adolescents, and young adults in the U.S.
- Led the implementation of clinical trial protocol aimed at assessing the safety and efficacy of Merck's Ebola vaccine among health and other frontline workers in Sierra Leone
- Led technical assistance on meningococcal disease surveillance systems strengthening in African countries of the meningitis belt through a Gates Foundation-funded consortium
- Led a meta-analysis on the burden and epidemiology of Pertussis in Latin America.
- Led protocol development for a \$200,000 NIH funded MSM carriage study in New York City

***Technical Assistance (Domestic/International)***

- Technical desk officer for Ebola Infection Prevention and Control (IPC) activities in Liberia at CDC's Emergency Operations Center (EOC): interfaced with NGOs for partnerships and collaborations on IPC activities. Co-developed training materials for healthcare workers on IPC.
- Led technical assistance to Nigeria's National Primary Health Care Agency (NPHCDA) as management support specialist to monitor the implementation of supplementary immunization activity to stop the transmission of measles
- Provided technical assistance to the Chicago City Department of Public Health (CDPH) in response to a meningococcal disease outbreak. Conducted survey and data analyses to inform vaccine campaign strategy in which over 11,000 men were vaccinated.
- Supported Serogroup B meningococcal vaccine campaign for college students at Princeton University in response to a Serogroup B *Neisseria Meningitidis* outbreak.

***Vaccine Policy Development and Other Activities***

- Conducted GRADE analysis on the evidence for the use of two newly licensed Meningitis B vaccines in the U.S among adolescents and young adults in the U.S.
- Co-developed communication materials on vaccine-preventable diseases for CDC's website.
- Provided consultation on enquiries by clinicians and the public on vaccine-preventable diseases including Pertussis, Tetanus, *Neisseria Meningitidis*, Diphtheria, and Hemophilus influenza.
- Supported a serogroup B *Neisseria Meningitidis* carriage study among college students in partnership with the Rhode Island Department of Health.
- Led analysis using surveillance data to examine the epidemiology of meningococcal disease risk among men who have sex with men (MSM) in the United States.

***National Program Analyst*****United Nations Population Fund (UNFPA), Lagos, Nigeria****January 2014- June 2014**

- Led technical support to state partners for the implementation of their annual work plans and evaluated state partners' budget and justification for UNFPA funded programs.
- Analyzed and interpreted the political, social, and economic environment relevant to population and development, reproductive health, and gender and identify opportunities for UNFPA assistance.
- Implemented various skills training for health workers focused on HIV prevention, Gender, and Women Development, and Maternal and Child Health among others.
- Co-developed national resource mobilization plan on the adolescent health for the UNFPA country office and knowledge document and work plan for a project targeted towards adolescent girls.

***Consultant/Senior Research Fellow*****Institute of Public Health, Obafemi Awolowo University, Ile-Ife, Nigeria****April-August 2011**

- Evaluated the data management system of the World Bank assisted Health Systems Development Project-II in Enugu State, Nigeria, and developed a technical report on the findings.

- Wrote technical papers that examined key public health and development issues across Africa; these included technical papers on food security, mHealth, and malaria treatment practices in Africa.
- Technical resource person at a national forum on young people's health and development, Abuja Nigeria: co-designed regional work plan for the implementation of the strategic framework on adolescent health in Nigeria as part of a team.

### ***Medical Officer***

**Bindawa Local Government Comprehensive Health Centre, Katsina, Nigeria**

**April 2010-March 2011**

- Led a medical team of 20 healthcare staff and provided daily clinical consultations to over 50 primary care clients including women, children, and older adults in a highly underserved region of Nigeria.
- Provided consultation on a variety of illnesses and preventive services ranging from immunization, treatment of malaria, URTIs, diarrheal illnesses, and, diagnosis, management, and referrals for hypertensive and diabetic illnesses, and, HIV counseling, testing, and referrals.
- Initiated health education programs for pregnant women and new mothers to increase uptake of childhood immunizations and appropriate weaning diet for children.

### ***Medical Intern***

**Obafemi Awolowo University Hospitals, Ile-Ife, Osun State, Nigeria**

**April 2009 - March 2010**

- Served as first doctor on call for emergency patient care and general management of ward patients.
- Rotated through departments of medicine, surgery, pediatrics, obstetrics, and gynecology, diagnosing and treating various clinical conditions.
- Evaluated patients with various health conditions, performed diagnostic work up, reviewed results and instituted appropriate treatments. Provided clinic follow up, referral and specialty consults.
- Provided reproductive health services including family planning, post-abortion care, antenatal and post-natal care. Implemented protocols for the prevention of mother-to-child transmission of HIV.
- Supported the scale-up of HIV antiretroviral drugs access to about 150 clients weekly in rural communities through the Clinton Foundation-funded Pediatric HIV Treatment Access Program. Tracked expenses linked with project activities, patient treatment outcomes, and laboratory investigations.
- Analyzed patient data to identify disease trends, risk factors, and patient outcomes. Presented findings at departmental research seminars.

### **EDUCATION**

---

- |      |   |
|------|---|
| 2026 | Master of Business Administration, Wharton School, University of Pennsylvania (in-view) |
| 2013 | Master of Public Policy (MPP), University of Oxford, United Kingdom                     |
| 2012 | Master of Public Health (MPH), Harvard University, Cambridge, Massachusetts             |
| 2011 | Certificate in Humanitarian Studies, Harvard University, Cambridge, Massachusetts       |
| 2008 | Bachelor of Medicine and Surgery (MBChB), Obafemi Awolowo University. Ile-Ife, Nigeria  |

### **PROFESSIONAL SOCIETY MEMBERSHIP**

---

- Infectious Disease Society of America, Member, 2019
- British Royal Society of Public Health, Fellow, 2013
- Nigerian Leadership Initiative, Associate Fellow, 2013
- Nigerian Medical Association, Member, 2009

### **PROFESSIONAL TRAINING/LICENSURES**

---

- Harvard School of Public Health, Principles and Practice of Clinical Research, 2021
- McKinsey Black Executive Leadership Program, 2020
- Advanced Course of Vaccinology (ADVAC), University of Geneva, May 2019
- Foreign Affairs Counter Threat Training, Federal Law Enforcement Training Centers, 2016
- Epidemic Intelligence Service Fellowship, US Centers for Disease Control, 2014-2016
- Humanitarian Studies Certificate Course, Harvard University, April 2011
- General Medical Practice License, Medical and Dental Council of Nigeria, 2009

## RELEVANT PUBLICATIONS

---

- Cripps AW, **Folaranmi T**, Johnson KD, Musey L, Niederman MS, Buchwald UK. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. *Expert Rev Vaccines*. 2021 Mar 2;1-11. doi: 10.1080/14760584.2021.1889374. Epub ahead of print. PMID: 33567914.
- Niederman MS, **Folaranmi T**, Buchwald UK, Musey L, Cripps AW, Johnson KD. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. *Expert Rev Vaccines*. 2021 Feb 20;1-13. doi: 10.1080/14760584.2021.1880328. Epub ahead of print. PMID: 33478306.
- Cui YA, **Folaranmi T**, Buchwald UK. The Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial: Further reflections on the design and results. *Vaccine*. 2021 Jan 22;39(4):641-643. doi: 10.1016/j.vaccine.2020.12.033. Epub 2020 Dec 23. PMID: 33358263.
- Buchwald UK, **Folaranmi T**, Weiss T. Response to Shami et al. 'Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong' (*Hum Vacc Immunother* 2020) [published online ahead of print, 2020 Jul 2]. *Hum Vaccin Immunother*. 2020;1-3. doi:10.1080/21645515.2020.1764828
- Nakamura A, Kawakami K, Wakana A, **Folaranmi TA**, Lino T. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude [published online ahead of print, 2020 Feb 11]. *Hum Vaccin Immunother*. 2020;1-8. doi:10.1080/21645515.2020.1717184
- Kawakami K, Nakamura A, Wakana A, **Folaranmi TA**, Lino T. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older [published online ahead of print, 2019 Dec 4]. *Hum Vaccin Immunother*. 2019;1-8. doi:10.1080/21645515.2019.1690332
- **Folaranmi T**; Rubin L; Martin S; Patel M & MacNeil J. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. *MMWR* 64 (22), 608-12.
- MacNeil J; Rubin L; **Folaranmi T**; Patel M & Martin S. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices (ACIP), Oct 2015. *MMWR*. 64(41); 1171-6.
- **Folaranmi T**, Kretz C., Kamiya H., MacNeil J., Whaley M., et al. Increased Risk for Meningococcal Disease among Men who have Sex with Men in the United States, 2012-2015. *Clin Infect Dis*. 2017 Sep 1;65(5):756-763. doi: 10.1093/cid/cix438.
- **Folaranmi T**, Pinell-McNamara V, Griffith M, Hao Y, Coronado F, Briere EC. Systematic review and meta- analysis of pertussis epidemiology in Latin America and the Caribbean: 1980–2015. *Rev Panam Salud Publica*. 2017;41:e102. doi: 10.26633/RPSP.2017.102.
- Wyber R.; Vaillancourt S.; Perry W.; Mannava P.; **Folaranmi T**.; & Celi L. A. Big data in global health: improving health in low- and middle-income countries. *Bulletin of the World Health Organization* 2015; 93:203-208.
- **Folaranmi T**. Adoption of mHealth in Africa: Opportunities and Challenges. *Perspectives in Public Health*. Jan.2014 vol. 134 no. 1 14-15.
- Omole o., **Folaranmi T**. Zika virus in Africa: revitalising the discourse of health systems. *Perspectives in Public Health*. Nov 2016. Vol 136, Issue 6, 2016.
- Awosusi A, **Folaranmi T** & Yates R. Nigeria's new government and public financing for Universal Health Coverage. *Lancet Global Health* Volume 3, No. 9, e514–e515, September 2015.
- **Folaranmi T**. & Sridhar D. "Financing a Post 2015 Health Agenda"— article in *Global Development Goals: Leaving no one behind*. A United Nations Association UK (UNA-UK) publication - September 2013

## AWARDS, FELLOWSHIPS & RECOGNITION

---

- Merck Excel Award for Fostering Collaborations, 2017
- CDC Honors Award for Excellence in Program Delivery, 2015
- CDC Ebola Response Award for Excellence in Program Delivery, 2014
- Blavatnik/BP Scholar, Oxford University, 2012

- Jeane Sauvé Public Leadership Fellow, McGill University, 2011
- Travel Scholarship, International Microbicides Conference on HIV Prevention, Pittsburgh, 2010
- Global Health Travel Award Recipient - Keystone Symposia, Tanzania. 2009
- Valedictorian, Obafemi Awolowo University Medical School, Ile- Ife, Nigeria Feb. 2009
- New Investigator in Global Health Award, Global Health Conference Washington D.C, 2008
- Federal Government University Scholarship, 2005
- ExxonMobil University Scholarship 2002-2008

## **RECENT SPEAKING ENGAGEMENTS**

---

Keynote Speaker, High Level Forum on Silver Economy, New York City, Dec 2023

Panel Speaker, Reuters Events: Pharma USA 2023

Panel Speaker, World Vaccines Congress, Washington DC, April 2024

Panel Speaker, Medical Affairs Strategic Summit, Jersey City, May 2024

## **MEDIA APPEARANCES**

---

**Immunization: An innovative strategy in race to save lives.** PhilStar Global Newspaper May 28, 2018

Read more at <https://www.philstar.com/business/business-as-usual/2018/05/28/1819174/immunization-innovative-strategy-race-save-lives#64a6ZGL9x2Dzlx0q.99>

**For 60-Plus Years, Respiratory Syncytial Virus (RSV) Vaccines Have Evaded Scientists. But Now That's Changed.** Scientific American. January 30, 2024. Read more at [For 60-Plus Years, Respiratory Syncytial Virus \(RSV\) Vaccines Have Evaded Scientists. But Now That's Changed | Scientific American](#)